



REGULATED INFORMATION

**PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN
LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF
MAJOR SHAREHOLDINGS (THE “TRANSPARENCY LAW”)**

GHENT, Belgium, 25 March 2010 – Ablynx [*Euronext Brussels: ABLX*], the biopharmaceutical company focused on the discovery and development of Nanobodies[®], announces, in accordance with Article 14 of the Belgian Law of 2 May 2007 regarding the publication of major shareholdings in issuers whose securities are admitted to trading on a regulated market (the "**Transparency Law**"), it received the following notifications of holdings between 22 March 2010 and 25 March 2010.

Notifying person(s)	Number of voting rights	Percentage of voting rights
Gimv NV, Adviesbeheer Gimv Life Sciences NV, Adviesbeheer Gimv Life Sciences 2004 NV and Biotech Fonds Vlaanderen NV¹	7,991,430	18.33%
C.H. Boehringer Sohn AG & Co. KG and Boehringer Ingelheim International GmbH²	2,142,857	4.92%
Multifund B.V., Nederlandia Investments B.V. and Stichting Avivia³	1,900,000	4.36%
KBC Group and KBC Private Equity⁴	1,264,822	2.90%

¹ Gimv NV controls Adviesbeheer Gimv Life Sciences NV and Adviesbeheer Gimv Life Sciences 2004 NV. Gimv NV (3,374,626 voting rights), Adviesbeheer Gimv Life Sciences NV (555,523 voting rights), Adviesbeheer Gimv Life Sciences 2004 NV (40,000 voting rights), and Biotech Fonds Vlaanderen NV (4,021,281 voting rights) are acting in concert. The Flemish Region is the ultimate shareholder of Biotech Fonds Vlaanderen NV.

² C.H. Boehringer Sohn AG & Co. KG (0 voting rights) is the parent undertaking controlling Boehringer Ingelheim International GmbH (2,142,857 voting rights).

³ Multifund B.V. (570,000 voting rights) is entrusted with the management and the exercise of the voting rights. Stichting Avivia controls Nederlandia Investments B.V. (1,330,000 voting rights).

⁴ KBC Group NV (0 voting rights) is the parent company, of which KBC Bank NV (0 voting rights) is a direct subsidiary. KBC Private Equity NV (1,264,822 voting rights) is a direct subsidiary of KBC Bank NV.

The total number of voting securities (denominator) and the total number of voting rights of Ablynx amount to 43,590,173.

Full versions of all transparency notifications are available on the website of Ablynx (www.ablynx.com – investor relations).

-ends-

About Ablynx [*Euronext Brussels: ABLX*] - <http://www.ablynx.com>

Founded in 2001 in Ghent, Belgium, Ablynx is a biopharmaceutical company focused on the discovery and development of Nanobodies, a novel class of therapeutic proteins based on single-domain antibody fragments,

for a range of serious and life-threatening human diseases. The Company currently has over 230 employees. Ablynx completed a successful IPO on Euronext Brussels [ABLX] on 7 November 2007 and raised €50 million through an SPO in March 2010.

Ablynx is developing a portfolio of Nanobody-based therapeutics in a number of major disease areas, including inflammation, thrombosis, oncology and Alzheimer's disease. Ablynx now has over 25 programmes in its therapeutic pipeline including four Nanobodies in clinical development. So far, Nanobodies have been successfully generated against more than 190 different protein targets including several complex targets such as chemokines, GPCRs, ion channels and viruses, which are typically very difficult to address with conventional monoclonal antibodies. Efficacy data have been obtained in 28 *in vivo* models for Nanobodies against a range of different targets.

Ablynx has an extensive patent position in the field of Nanobodies for healthcare applications. It has exclusive and worldwide rights to more than 130 families of granted patents and pending patent applications, including the Hamers patents covering the basic structure, composition, preparation and uses of Nanobodies.

Ablynx has ongoing research collaborations and significant partnerships with several major pharmaceutical companies, including Boehringer Ingelheim, Merck Serono, Novartis and Pfizer (previously Wyeth Pharmaceuticals). Ablynx is building a diverse and broad portfolio of therapeutic Nanobodies through these collaborations as well as through its own internal discovery programmes.

The Company's lead programme ALX-0081, an intravenously administered novel anti-thrombotic, entered a Phase II study in patients undergoing percutaneous coronary intervention (PCI) in September 2009. Ablynx demonstrated proof-of-concept by biomarker for ALX-0081 in December 2009. ALX-0681, a subcutaneous administration of the anti-von Willebrand factor (vWF) Nanobody recently concluded a Phase I study.

In September 2009, Ablynx's partner Pfizer entered a Phase II study in RA patients, with an anti-TNF-alpha Nanobody.

In December 2009, Ablynx initiated a double-blind, randomised, placebo-controlled Phase I study with ALX-0141, a Nanobody targeting Receptor Activator of Nuclear Factor kappa B Ligand (RANKL), in healthy postmenopausal women. ALX-0061, an anti-IL6R Nanobody is in preclinical development for the treatment of autoimmune and inflammatory diseases. In February 2010, Ablynx announced that it had reached its criteria for initiating the preclinical development of ALX-0651, a Nanobody against CXCR4, and will progress this programme towards the clinic. CXCR4 plays an important role in cell mobility, tumor growth and metastasis.

For more information, please contact Ablynx:

Dr Edwin Moses
Chairman and CEO
t: +32 (0)9 262 00 07
m: +44 (0)7771 954 193 /
+32 (0)473 39 50 68
e: edwin.moses@ablynx.com

Eva-Lotta Allan
Chief Business Officer
t: +32 (0)9 262 00 75
m: +32 (0)475 78 36 21 /
+44 (0)7990 570 900
e: eva-lotta.allan@ablynx.com

Wim Ottevaere
Chief Financial Officer
t: +32 (0)9 262 00 08
e: wim.ottevaere@ablynx.com

Certain statements, beliefs and opinions in this press release are forward-looking, which reflect the Company's or, as appropriate, the Company's directors' current expectations and projections about future events. By their nature, forward-looking statements involve a number of risks, uncertainties and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Forward looking statements contained in this press release regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. As a result, the Company expressly disclaims any obligation or undertaking to release any update or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward-looking statements are based. Neither the Company nor its advisers or representatives nor any of its or their parent or subsidiary undertakings or any such person's officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.